Carbonic Anhydrases III and IV Autoantibodies in Rheumatoid Arthritis, Systemic Lupus Erythematosus, Diabetes, Hypertensive Renal Disease, and Heart Failure
Table 3
The antioxidant enzyme activity and MDA of subjects (mean (SD)).
RA
SLE
T1D
T1DN
T2D
T2DN
HTN
HT
SOD (U/mL)
control
134.57 (13.13)
151.55 (14.97)
142.83 (13.98)
145.66 (17.97)
139.63 (22.80)
141.10 (21.57)
149.00 (18.92)
142.13 (16.30)
patients
92.85* (36.87)
105.60* (33.55)
131.19 (23.98)
133.68* (31.36)
131.69 (43.67)
115.37* (38.56)
131.69* (42.36)
101.93* (36.34)
GPx (U/mL)
control
158.18 (34.41)
171.20 (45.60)
162.68 (42.02)
159.67 (37.94)
164.36 (41.25)
155.39 (44.98)
157.65 (39.86)
159.36 (41.23)
patients
118.29* (40.30)
135.85* (41.97)
146.58* (39.23)
127.96* (43.63)
159.67 (34.76)
161.33 (45.68)
149.35 (48.64)
135.36* (45.39)
CAT (U/mL)
control
1.42 (0.45)
1.56 (0.37)
1.54 (0.55)
1.39 (0.36)
1.74 (0.45)
1.61 (0.47)
1.52 (0.51)
1.73 (0.41)
patients
1.33 (0.56)
1.37 (0.53)
1.39 (0.59)
1.11* (0.42)
1.25* (0.51)
1.33* (0.51)
1.47 (0.31)
1.39* (0.63)
TAC (U/mL)
control
14.31 (5.13)
15.12 (3.35)
15.65 (3.63)
14.96 (4.32)
15.69 (3.36)
16.01 (4.51)
14.63 (3.39)
14.78 (4.13)
patients
11.25* (4.56)
13.59 (6.65)
14.32 (4.13)
12.15* (5.30)
14.34 (4.69)
14.96 (6.66)
13.97 (4.63)
12.01* (5.22)
MDA (nmol/mL)
control
3.57 (1.01)
3.31 (0.94)
3.14 (1.02)
3.46 (1.32)
3.35 (0.85)
3.61 (0.98)
3.44 (1.13)
3.57 (1.20)
patients
4.52* (1.25)
4.29* (1.37)
3.08 (1.33)
4.05* (1.25)
3.45 (1.09)
3.96 (1.23)
3.55 (1.15)
4.11* (0.87)
*There were significant differences between patients and control (P < 0.05). HTN: hypertensive nephropathy; HT: heart failure.
